Welcome to Glycotope

Targeting tumor-specific glycosylation patterns to enable advanced therapies

We are Glycotope

We are dedicated to improving the lives of cancer patients by enabling treatment options that go beyond today’s standard of care.

With exceptional experience in glycobiology and therapeutic antibody development, our mission is to develop advanced biologics that facilitate novel approaches to cancer therapies.

Setting new standards of tumor-specificity in antibody therapeutics

About Us

Learn More about Glycotope and our Leadership Team

Learn more

Technology

Our proprietary technology platform enables the development of antibodies with unrivaled tumor-specificity

Learn more

Pipeline

Our pipeline of antibody therapeutics includes in-house and partnered pre-clinical programs

Learn more

Partners

We aim to continuously expand our collaborations with industry partners and academic centers to further exploit the unique potential of our technology

Learn more

News

3. November 2023
Glycotope Presents anti-GlycoTarget Antibodies at the 2023 Society for Immunotherapy of Cancer (SITC) Meeting
Read Article
16. October 2023
LegoChem Biosciences Enters Worldwide Licensing Agreement with Glycotope for Antibody Drug Conjugate Development
Read Article
25. September 2023
Glycotope and Max Delbrück Center enter into research collaboration to explore combination of GlycoTargets and CAR technology
Read Article
Read All